Recent developments in therapeutic strategies have provided alternatives to corticosteroids
as the cornerstone treatment for managing airway inflammation in asthma. The past two …

IgE is central to the pathophysiology of allergic asthma. Omalizumab, a humanized anti-IgE
mAb, specifically binds free IgE and interrupts the allergic cascade by preventing binding of …

Severe asthma imposes a significant burden on patients, families and healthcare systems.
Management is difficult, due to disease heterogeneity, co‐morbidities, complexity in care …

Background Severe Asthma Network in Italy (SANI) is a registry of patients recruited by
accredited centers on severe asthma. Objective To analyze epidemiological, clinical …

Omalizumab was the first, and for a long time the only available monoclonal antibody for the
add-on treatment of severe allergic asthma. In particular, omalizumab selectively targets …

Background While up to 50% of patients with severe asthma have no evidence of allergy,
IgE has been linked to asthma, irrespective of atopic status. Omalizumab, an anti-IgE …

Asthma is a chronic inflammatory disorder of the airways that leads to acute symptoms,
exacerbations and sometimes, for a small part of the asthmatic population, fatal or near-fatal …

Abstract Background Omalizumab (anti-IgE monoclonal antibody) is an approved add-on
therapy for Japanese patients with severe allergic asthma. As directed by the Ministry of …

The off-label use of medicines is a common and extensive clinical practice. Omalizumab has
been licensed for use in severe allergic asthma and chronic urticaria. Omalizumab dosing …

IgE is the least abundant Ig isotype, yet it plays a critical role in allergic reactions and host
protection from helminth infection. Although IgE was discovered 50 years ago, the ultimate …